Find information on thousands of medical conditions and prescription drugs.

Cilastatin

Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Dehydropeptidase is found in the kidney and is responsible for degrading the antibiotic imipenem. Cilastatin is therefore given intravenously with imipenem in order to protect imipenem from dehydropeptidase and allow it to kill bacteria. However, cilastatin itself does not have any antibiotic activity.

An example of an Imipenem and Cilastatin combination therapy is the Merck drug Primaxin (also known as Tienam).

A

B

C

Calcium folinate

Chenodeoxycholic acid

Chloramphenicol

Chlordiazepoxide

Chlorprothixene

Chlortetracycline

Choriogonadotropin alfa

Chorionic gonadotropin

Clavulanic acid

Cyclobenzaprine

Cyclophosphamide

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Read more at Wikipedia.org

• [List your site here Free!]


		Imipenem/Cilastatin: Experience With a Long Acting Intramuscular Formulation (Chemotherapy, Vol 37, Suppl 2, 1991) $18.50


	Effects of manipulation of N-methyl-D-aspartate receptors on imipenem/cilastatin-induced seizures in rats Background & objectives: Epileptic seizures have been reported in patients on imipenem/cilastatin (Imi/Cil) therapy. To investigate contribution of N-methyl-D-aspartate ... From Indian Journal of Medical Research, 2/1/04 by Zivanovic, Dragana

	Atypical infections in tsunami survivors After a tsunami hit Asia in December 2004, 2 survivors had severe infections due to multidrug-resistant and atypical bacteria and rare fungi weeks afterwards. From Emerging Infectious Diseases, 10/1/05 by Christian Garzoni

	Impact of clinical guidelines in the management of severe hospital-acquired pneumonia Study objectives: To asses the impact of locally developed antimicrobial treatment guidelines in the initial empiric treatment of ICU patients with severe hospital-acquired pneumonia (HAP). Desig From CHEST, 10/1/05 by Guy W. Soo Hoo

	Merrem approved for skin infections The FDA recently approved Astra Zeneca's antibiotic Merrem IV (meropenem) for the treatment of complicated skin and skin structure infections including ... From Journal of Drugs in Dermatology, 9/1/05

	FDA approves Tygacil for the treatment of complicated skin and skin structure infections The FDA recently approved Tygacil for the intravenous treatment of complicated skin and skin structure infections, including infected burns, deep soft ... From Journal of Drugs in Dermatology, 9/1/05

	Fibroblast growth factor improves wound healing Chicago -- Wound bed preparation and surgical reconstruction of acute, intensive wounds can be improved with the use of artificial skin substitute and ... From Cosmetic Surgery Times, 9/1/05 by Barbara J. Rutledge

	Infections of Febrile Neutropenic Patients in Malignant Hematological Diseases (Second Study Period) Sixty-one febrile episodes among 27 neutropenic patients with malignant hematological diseases were studied during a study period between 1998 and 2001. From Military Medicine, 8/1/05 by Rókusz, László

	Quinolone safety and efficacy To the Editor: Richard Frothingham should be commended for providing added perspective on the matter of quinolone selection. His letter to the editor ... From Emerging Infectious Diseases, 6/1/05 by Spartaco Bellomo

Home

Contact

Resources

ebay